Assessing cognitive dysfunction in breast cancer: what are the tools?

Area of Science:

• Neuropsychology
• Oncology
• Cognitive Science

Background:

• Adjuvant chemotherapy for breast cancer aims to reduce recurrence and mortality.
• Chemotherapy can negatively impact patients' quality of life, causing fatigue and mood alterations.
• Cognitive deficits are common during and after chemotherapy, affecting daily functioning.

Purpose of the Study:

• To provide an overview of neuropsychology and chemotherapy's cognitive effects.
• To summarize existing research on chemotherapy-related cognitive dysfunction in breast cancer patients.
• To compare cognitive performance in women actively receiving chemotherapy versus those post-treatment.

Main Methods:

• Review of neuropsychological measures for assessing chemotherapy's cognitive effects.
• Summary of current literature on cognitive impairment in breast cancer patients undergoing chemotherapy.
• Pilot study comparing cognitive performance of women in active chemotherapy versus 6-12 months post-chemotherapy.

Main Results:

• Chemotherapy is associated with decreased cognitive functioning, fatigue, and mood alterations.
• Standardized neuropsychological measures are crucial for objective assessment.
• Ongoing pilot study compares cognitive performance across different treatment phases.

Conclusions:

• Neuropsychological assessment is vital for understanding and managing chemotherapy's cognitive side effects.
• Further research is needed to refine tools for detecting short-term and persistent cognitive changes.
• Individualized tracking of neurocognitive changes across treatment phases is essential.